BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 19154451)

  • 21. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
    Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
    Giesing M; Suchy B; Driesel G; Molitor D
    BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.
    Allgayer H; Heiss MM; Riesenberg R; Grützner KU; Tarabichi A; Babic R; Schildberg FW
    Cancer Res; 1997 Apr; 57(7):1394-9. PubMed ID: 9102229
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients.
    Gupta A; Lotan Y; Ashfaq R; Roehrborn CG; Raj GV; Aragaki CC; Montorsi F; Shariat SF
    Eur Urol; 2009 May; 55(5):1124-33. PubMed ID: 18585843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis.
    Shariat SF; Roehrborn CG; McConnell JD; Park S; Alam N; Wheeler TM; Slawin KM
    J Clin Oncol; 2007 Feb; 25(4):349-55. PubMed ID: 17264329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
    Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
    BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [PSA and follow-up after treatment of prostate cancer].
    Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
    Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting uPA/uPAR in prostate cancer.
    Li Y; Cozzi PJ
    Cancer Treat Rev; 2007 Oct; 33(6):521-7. PubMed ID: 17658220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in prostate cancer diagnosis and prognosis: beyond prostate-specific antigen.
    Fradet Y
    Curr Opin Urol; 2009 May; 19(3):243-6. PubMed ID: 19325493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.
    Riethdorf S; Pantel K
    Pathobiology; 2008; 75(2):140-8. PubMed ID: 18544969
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localized prostate cancer: can we better define who is at risk of unfavourable outcome?
    Joniau S; Van Poppel H
    BJU Int; 2008 Mar; 101 Suppl 2():5-10. PubMed ID: 18307686
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumour cells in cancer patients: challenges and perspectives.
    Pantel K; Alix-Panabières C
    Trends Mol Med; 2010 Sep; 16(9):398-406. PubMed ID: 20667783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer micrometastasis and tumour dormancy.
    Wikman H; Vessella R; Pantel K
    APMIS; 2008; 116(7-8):754-70. PubMed ID: 18834417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum markers for prostate cancer: a rational approach to the literature.
    Steuber T; O'Brien MF; Lilja H
    Eur Urol; 2008 Jul; 54(1):31-40. PubMed ID: 18243505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Other biomarkers for detecting prostate cancer.
    Nogueira L; Corradi R; Eastham JA
    BJU Int; 2010 Jan; 105(2):166-9. PubMed ID: 19930175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer.
    Shariat SF; Karam JA; Margulis V; Karakiewicz PI
    BJU Int; 2008 Mar; 101(6):675-83. PubMed ID: 17941930
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.